Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CymaBay Alters NASH Hypothesis After Phase IIb Failure In Hepatic Fat Reduction

Executive Summary

Firm points to liver biomarker findings, saying they may yield clear liver benefit at 52 weeks. Both CymaBay's and Genfit's stock prices fell as investors wondered about broader read-through for the PPAR agonist class.

Advertisement

Related Content

CymaBay Following The Leaders, Pursues NASH, PBC Simultaneously
NASH News & Notes From The European Liver Meeting
Genfit Hopes To Make Case For First-Line Treatment In NASH
NASH Pipeline: Racing To The Finish
Intercept Retakes The Lead In NASH
NASH Drug Development Guidance Encourages Sponsors To Adopt Innovative Trial Designs

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC125374

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel